You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
向日葵(300111.SZ)擬售向日光電、聚輝新能源各100%股權 主營聚焦醫藥製造業
格隆匯 12-03 20:45

格隆匯12月3日丨向日葵(300111.SZ)披露重大資產出售暨關聯交易報告書(草案),公司擬將其持有的向日光電100%股權、聚輝新能源100%股權轉讓予向日葵投資,向日葵投資以現金方式支付全部交易對價。

截至評估基準日,向日光電100%股權的評估價值為-56262.76萬元,聚輝新能源100%股權的評估價值為23837.40萬元。

向日葵同意於交割日起豁免其對向日光電子公司盧森堡向日葵、香港向日葵、德國向日葵享有的合計544,578,540.54元的債權,同時,向日光電於交割日起豁免其對向日葵享有的合計14,548,899.06元的債權。

綜合考慮評估價值與上述約定,雙方協商確定此次交易向日光電100%股權的交易價格為1元,聚輝新能源100%股權的交易價格為2.39億元,交易價格合計2.39億元。

此次交易的交易對方向日葵投資的股東為胡愛和吳靈珂,胡愛與公司實際控制人吳建龍為夫妻關係,吳靈珂與吳建龍為父子關係,因此此次交易構成關聯交易。

通過收購貝得藥業60%股權,公司的主營業務拓展至醫藥製造業,實現光伏和醫藥雙主業發展的格局。醫藥製造業務已成為上市公司新的利潤增長點,上市公司的盈利能力和資產質量逐步提高。公司從事光伏行業多年,主要管理人員具有豐富的光伏電池行業經驗。然而,隨着近年來光伏政策的不斷調整,加速了“平價上網”的實現,公司面臨產品單價和毛利率持續下降的風險。為此,公司管理層密切關注行業動態及政策導向,審慎決定處置光伏相關業務,提升公司的盈利能力、改善資產質量。

通過此次交易,公司的主營業務將聚焦醫藥製造業,未來公司將利用上市公司平台優勢,整合自身的管理經驗、資本運作能力,把資金、人員等優先配置予貝得藥業,全面提升貝得藥業在醫藥製造領域的資源和技術積累,實現未來可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account